Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GeoVax Labs has said that its HIV/AIDS vaccine is one of the select few to move forward into Phase IIa human trials by the HIV Vaccine Trials Network or HVTN, a network supported by the National Institutes of Health.
Subscribe to our email newsletter
According to the company, this newly planned Phase II trial is tentatively scheduled to start mid-2008 and will involve up to 500 participants at several locations in the US.
Harriet Robinson, senior vice president, R&D at GeoVax, said: “Our vaccine continues to demonstrate the promise of not only being safe but also effective at eliciting potentially protective immune responses.”